Novo Nordisk: Massive buying opportunityNovo has been struggling big time, december and march hit especially hard.
American institutions have held large positions in Novo, and this was felt when they had to sell off due to risk management with the looming tariffs.
However, the sheer devaluation & importance of their export, is going to
Key facts today
Novo Nordisk will skip early development and start late-stage trials for its obesity drug, amycretin, in early 2026. Analysts note promising results, with a 22% weight loss at the highest dose.
Novo Nordisk signed an $812 million licensing deal with U.S. biotech Deep Apple for a weight-loss drug and announced a partnership with Septerna to develop oral small-molecule weight-loss drugs.
Novo Nordisk A/S released its Quarterly Trading Report for Q1 2025, providing insights into the company's financial performance and market activities during the first quarter of the year.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
3.013 CHF
12.69 B CHF
36.50 B CHF
3.16 B
About NOVO NORDISK B A/S
Sector
Industry
CEO
Lars Fruergaard Jørgensen
Website
Headquarters
Bagsværd
Founded
1931
ISIN
DK0062498333
FIGI
BBG006M6YKB4
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.
NOVO is looking at a strong bullish bottoming outNYSE:NVO is looking at a strong bullish reversal and is likely to head higher after stochastic shows overbought AND long term stochastic shows clear confirmation of oversold crossover.
Price action shows a clear break out of the downtrend line and with the rounding bottom, the stock is likely to
nvo bullish long Long Setup Idea – Not Financial Advice - AH
This is a long trade setup based on my personal analysis.
The entry, stop-loss, and target levels are outlined for educational and illustrative purposes only.
📈 Entry:
🛑 Stop Loss:
🎯 Target(s):
Disclaimer:
I am not a financial advisor. This idea i
NVO Soaring Towards TargetsOur NVO call debit spreads and LEAPS options soaring towards targets at the 233 EMA here.
Beautiful thing when fundamentals, valuations and technicals align.
Impulse move from the bottom gave us a hat trick - triple green tags (white circles) for bullish A+ momentum signals into a consolidation p
NVO Exhibits High Monthly Volume Amid Downtrend – SHortNVO Exhibits High Monthly Volume Amid Downtrend – Potential Accumulation Phase
📉 Post:
Novo Nordisk (NVO) has experienced a significant decline from its 52-week high of $148.15 to a recent low of $57.00. However, the monthly chart reveals an unusually high trading volume, which may indicate accumul
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where NOV is featured.
Related stocks
Frequently Asked Questions
The current price of NOV is 65.027 CHF — it has decreased by −0.72% in the past 24 hours. Watch NOVO NORDISK A/S stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange NOVO NORDISK A/S stocks are traded under the ticker NOV.
NOV stock has risen by 7.05% compared to the previous week, the month change is a 17.87% rise, over the last year NOVO NORDISK A/S has showed a −49.43% decrease.
We've gathered analysts' opinions on NOVO NORDISK A/S future price: according to them, NOV price has a max estimate of 112.71 CHF and a min estimate of 43.83 CHF. Watch NOV chart and read a more detailed NOVO NORDISK A/S stock forecast: see what analysts think of NOVO NORDISK A/S and suggest that you do with its stocks.
NOV stock is 3.04% volatile and has beta coefficient of 1.42. Track NOVO NORDISK A/S stock price on the chart and check out the list of the most volatile stocks — is NOVO NORDISK A/S there?
Today NOVO NORDISK A/S has the market capitalization of 288.02 B, it has increased by 1.58% over the last week.
Yes, you can track NOVO NORDISK A/S financials in yearly and quarterly reports right on TradingView.
NOVO NORDISK A/S is going to release the next earnings report on Aug 6, 2025. Keep track of upcoming events with our Earnings Calendar.
NOV earnings for the last quarter are 0.84 CHF per share, whereas the estimation was 0.78 CHF resulting in a 6.95% surprise. The estimated earnings for the next quarter are 0.75 CHF per share. See more details about NOVO NORDISK A/S earnings.
NOVO NORDISK A/S revenue for the last quarter amounts to 10.02 B CHF, despite the estimated figure of 10.00 B CHF. In the next quarter, revenue is expected to reach 9.77 B CHF.
NOV net income for the last quarter is 3.72 B CHF, while the quarter before that showed 3.55 B CHF of net income which accounts for 4.95% change. Track more NOVO NORDISK A/S financial stats to get the full picture.
NOVO NORDISK A/S dividend yield was 1.83% in 2024, and payout ratio reached 50.28%. The year before the numbers were 1.35% and 50.35% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Jun 14, 2025, the company has 76.3 K employees. See our rating of the largest employees — is NOVO NORDISK A/S on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NOVO NORDISK A/S EBITDA is 20.12 B CHF, and current EBITDA margin is 50.95%. See more stats in NOVO NORDISK A/S financial statements.
Like other stocks, NOV shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NOVO NORDISK A/S stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NOVO NORDISK A/S technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NOVO NORDISK A/S stock shows the sell signal. See more of NOVO NORDISK A/S technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.